Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marion Hädrich

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Therapeutische Umschau. Revue Therapeutique|November 3, 2016
Johannes Lenglinger, Marion Hädrich
Case Reports in Hepatology|May 9, 2015
Acute Hepatitis Induced by Lyprinol, the Lipid Extract of the Green-Lipped Mussel (Perna canaliculus), in a Patient with PolyarthrosisAmr Abdulazim, Marion Hädrich, Matteo Montani, et al.
Histopathology|January 7, 2017
Comprehensive assessment of tumour budding by cytokeratin staining in colorectal cancerGregor Rieger, Viktor H Koelzer, Heather E Dawson, et al.
Clinical Colorectal Cancer|November 4, 2018
Stromal PD-1/PD-L1 Expression Predicts Outcome in Colon Cancer PatientsJacqueline Wyss, Bastian Dislich, Viktor H Koelzer, et al.
Journal of Translational Medicine|April 1, 2014
CD8/CD45RO T-cell infiltration in endoscopic biopsies of colorectal cancer predicts nodal metastasis and survivalViktor H Koelzer, Alessandro Lugli, Heather Dawson, et al.
Oncotarget|December 22, 2014
TWIST1 and TWIST2 promoter methylation and protein expression in tumor stroma influence the epithelial-mesenchymal transition-like tumor budding phenotype in colorectal cancerJosé A Galván, Melina Helbling, Viktor H Koelzer, et al.
Virchows Archiv : an International Journal of Pathology|February 22, 2015
Tumor budding in colorectal cancer revisited: results of a multicenter interobserver studyViktor H Koelzer, Inti Zlobec, Martin D Berger, et al.
Oncotarget|October 27, 2015
VE1 immunohistochemistry predicts BRAF V600E mutation status and clinical outcome in colorectal cancerChristian Schafroth, José A Galván, Irene Centeno, et al.
Oncotarget|July 13, 2014
Investigation of IL-23 (p19, p40) and IL-23R identifies nuclear expression of IL-23 p19 as a favorable prognostic factor in colorectal cancer: a retrospective multicenter study of 675 patientsMelina Helbling, Anne Lukesch, Aladin Haimovici, et al.
Clinical Epigenetics|September 28, 2018
CDX2 in colorectal cancer is an independent prognostic factor and regulated by promoter methylation and histone deacetylation in tumors of the serrated pathwayJanina Graule, Kristin Uth, Elia Fischer, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Therapeutische Umschau. Revue Therapeutique|November 3, 2016
Johannes Lenglinger, Marion Hädrich
Case Reports in Hepatology|May 9, 2015
Acute Hepatitis Induced by Lyprinol, the Lipid Extract of the Green-Lipped Mussel (Perna canaliculus), in a Patient with PolyarthrosisAmr Abdulazim, Marion Hädrich, Matteo Montani, et al.
Histopathology|January 7, 2017
Comprehensive assessment of tumour budding by cytokeratin staining in colorectal cancerGregor Rieger, Viktor H Koelzer, Heather E Dawson, et al.
Clinical Colorectal Cancer|November 4, 2018
Stromal PD-1/PD-L1 Expression Predicts Outcome in Colon Cancer PatientsJacqueline Wyss, Bastian Dislich, Viktor H Koelzer, et al.
Journal of Translational Medicine|April 1, 2014
CD8/CD45RO T-cell infiltration in endoscopic biopsies of colorectal cancer predicts nodal metastasis and survivalViktor H Koelzer, Alessandro Lugli, Heather Dawson, et al.
Oncotarget|December 22, 2014
TWIST1 and TWIST2 promoter methylation and protein expression in tumor stroma influence the epithelial-mesenchymal transition-like tumor budding phenotype in colorectal cancerJosé A Galván, Melina Helbling, Viktor H Koelzer, et al.
Virchows Archiv : an International Journal of Pathology|February 22, 2015
Tumor budding in colorectal cancer revisited: results of a multicenter interobserver studyViktor H Koelzer, Inti Zlobec, Martin D Berger, et al.
Oncotarget|October 27, 2015
VE1 immunohistochemistry predicts BRAF V600E mutation status and clinical outcome in colorectal cancerChristian Schafroth, José A Galván, Irene Centeno, et al.
Oncotarget|July 13, 2014
Investigation of IL-23 (p19, p40) and IL-23R identifies nuclear expression of IL-23 p19 as a favorable prognostic factor in colorectal cancer: a retrospective multicenter study of 675 patientsMelina Helbling, Anne Lukesch, Aladin Haimovici, et al.
Clinical Epigenetics|September 28, 2018
CDX2 in colorectal cancer is an independent prognostic factor and regulated by promoter methylation and histone deacetylation in tumors of the serrated pathwayJanina Graule, Kristin Uth, Elia Fischer, et al.
Pageof 1